Financials IMV Inc.

Equities

IMVIQ

CA44974L3011

Biotechnology & Medical Research

Market Closed - OTC Markets 03:53:34 2024-05-09 pm EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for IMV Inc. 0.00% -99.95%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 238.8 232.6 146.8 206.6 100.2 30.6
Enterprise Value (EV) 2 230.4 227.3 142.5 170.5 81.25 38.28
P/E ratio -19.2 x -10.3 x -5.26 x -5.33 x -2.47 x -0.53 x
Yield - - - - - -
Capitalization / Revenue - 2,837,182,512 x 2,488,635,983 x 68,882,701,000 x - -
EV / Revenue - 2,771,975,195 x 2,415,805,475 x 56,823,701,000 x - -
EV / EBITDA -20.7 x -11.3 x -5.43 x -4.29 x -2.1 x -0.97 x
EV / FCF -42.3 x -18.9 x -7.97 x -6.95 x -3.68 x -1.78 x
FCF Yield -2.36% -5.3% -12.5% -14.4% -27.2% -56.2%
Price to Book 38 x 54 x 22.8 x 5.25 x 4.65 x -3.52 x
Nbr of stocks (in thousands) 3,991 4,500 5,063 6,709 8,214 12,593
Reference price 3 59.84 51.70 29.00 30.80 12.20 2.430
Announcement Date 3/20/18 3/21/19 3/30/20 3/17/21 3/17/22 3/16/23
1USD in Million2CAD in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - 0.082 0.059 0.003 - -
EBITDA 1 -11.11 -20.1 -26.26 -39.77 -38.78 -39.58
EBIT 1 -11.25 -20.33 -26.64 -40.12 -39.1 -40.27
Operating Margin - -24,795.12% -45,144.07% -1,337,233.33% - -
Earnings before Tax (EBT) 1 -12.03 -21.94 -27.36 -34.86 -36.59 -37.99
Net income 1 -12.03 -21.94 -27.36 -34.86 -36.59 -37.99
Net margin - -26,750% -46,381.36% -1,161,833.33% - -
EPS 2 -3.112 -5.012 -5.511 -5.780 -4.931 -4.553
Free Cash Flow 1 -5.449 -12.06 -17.88 -24.52 -22.11 -21.51
FCF margin - -14,702.59% -30,300.42% -817,287.5% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/20/18 3/21/19 3/30/20 3/17/21 3/17/22 3/16/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales 1 0.088 0.089 0.0834 0.0526 0.051 0.0446 0.0312 0.0434 0.1578 0.2111
EBITDA 1 -8.468 -10.27 -8.49 -9.15 -12.83 -14.57 -13.08 -12.41 -11.7 -14.67
EBIT 1 -8.415 -10.36 -8.49 -9.304 -12.91 -14.35 -13.31 -12.69 -12.1 -12.35
Operating Margin -9,562.5% -11,643.82% -10,182.14% -17,674.73% -25,311.33% -32,182.04% -42,578.4% -29,246.54% -7,670.55% -5,848.39%
Earnings before Tax (EBT) 1 -8.327 -9.596 -8.406 -9.323 -12.98 -14.95 -13.7 -12.64 -11.95 -11.91
Net income 1 -8.327 -9.596 -8.406 -9.323 -12.98 -14.95 -13.7 -12.64 -11.95 -11.91
Net margin -9,462.5% -10,782.02% -10,082.14% -17,710.45% -25,460.12% -33,527.6% -43,845.06% -29,134.79% -7,570.55% -5,639.24%
EPS 2 -1.300 -1.400 -1.210 -1.376 -1.617 -1.770 -1.681 -1.531 -1.471 -1.311
Dividend per Share - - - - - - - - - -
Announcement Date 11/12/20 3/17/21 5/12/21 8/11/21 11/10/21 3/17/22 5/13/22 8/11/22 11/10/22 3/16/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - 7.67
Net Cash position 1 8.37 5.35 4.3 36.2 19 -
Leverage (Debt/EBITDA) - - - - - -0.1939 x
Free Cash Flow 1 -5.45 -12.1 -17.9 -24.5 -22.1 -21.5
ROE (net income / shareholders' equity) -181% -412% -508% -152% -140% -509%
ROA (Net income/ Total Assets) -43.8% -63.6% -73.4% -61.7% -50.8% -61.8%
Assets 1 27.48 34.49 37.28 56.46 71.96 61.49
Book Value Per Share 2 1.570 0.9600 1.270 5.870 2.620 -0.6900
Cash Flow per Share 2 3.700 3.300 2.780 6.910 4.700 2.220
Capex 1 0.39 2.19 0.48 0.44 1.4 1.07
Capex / Sales - 2,664.63% 806.78% 14,733.33% - -
Announcement Date 3/20/18 3/21/19 3/30/20 3/17/21 3/17/22 3/16/23
1CAD in Million2CAD
Estimates
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW